Corbus Pharmaceuticals Holdings Past Earnings Performance
Past criteria checks 0/6
Corbus Pharmaceuticals Holdings has been growing earnings at an average annual rate of 12.8%, while the Biotechs industry saw earnings growing at 12.7% annually. Revenues have been declining at an average rate of 65.8% per year.
Key information
12.8%
Earnings growth rate
28.9%
EPS growth rate
Biotechs Industry Growth | 17.0% |
Revenue growth rate | -65.8% |
Return on equity | n/a |
Net Margin | n/a |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Corbus: Ability To Have Best-In-Class Nectin-4 Targeting Drug
Jan 30Corbus Pharmaceuticals GAAP EPS of -$0.11
Aug 09Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Using Too Much Debt?
Nov 19Here's Why Shareholders Should Examine Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package More Closely
Jun 12Should Shareholders Reconsider Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) CEO Compensation Package?
May 14What Kind Of Shareholders Hold The Majority In Corbus Pharmaceuticals Holdings, Inc.'s (NASDAQ:CRBP) Shares?
Mar 11Is Corbus Pharmaceuticals Holdings (NASDAQ:CRBP) Weighed On By Its Debt Load?
Feb 04Corbus Pharmaceuticals: Down But Not Out
Jan 29Have Insiders Been Buying Corbus Pharmaceuticals Holdings, Inc. (NASDAQ:CRBP) Shares This Year?
Jan 09Corbus's lenabasum shows benefit in autoimmune disorder
Nov 09Revenue & Expenses BreakdownBeta
How Corbus Pharmaceuticals Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -45 | 14 | 0 |
30 Sep 23 | 0 | -47 | 15 | 0 |
30 Jun 23 | 0 | -46 | 16 | 0 |
31 Mar 23 | 0 | -51 | 17 | 0 |
31 Dec 22 | 0 | -42 | 19 | 0 |
30 Sep 22 | 0 | -42 | 18 | 0 |
30 Jun 22 | 0 | -35 | 20 | 0 |
31 Mar 22 | 0 | -39 | 20 | 0 |
31 Dec 21 | 1 | -46 | 20 | 0 |
30 Sep 21 | 2 | -44 | 22 | 0 |
30 Jun 21 | 3 | -77 | 24 | 0 |
31 Mar 21 | 3 | -98 | 26 | 0 |
31 Dec 20 | 4 | -111 | 28 | 0 |
30 Sep 20 | 6 | -129 | 29 | 0 |
30 Jun 20 | 7 | -115 | 27 | 0 |
31 Mar 20 | 36 | -75 | 25 | 0 |
31 Dec 19 | 36 | -71 | 24 | 0 |
30 Sep 19 | 35 | -62 | 21 | 0 |
30 Jun 19 | 34 | -56 | 19 | 0 |
31 Mar 19 | 6 | -70 | 17 | 0 |
31 Dec 18 | 5 | -56 | 13 | 0 |
30 Sep 18 | 3 | -49 | 12 | 0 |
30 Jun 18 | 3 | -41 | 11 | 0 |
31 Mar 18 | 2 | -37 | 10 | 0 |
31 Dec 17 | 2 | -32 | 9 | 0 |
30 Sep 17 | 3 | -29 | 9 | 0 |
30 Jun 17 | 3 | -28 | 9 | 0 |
31 Mar 17 | 3 | -25 | 8 | 0 |
31 Dec 16 | 2 | -20 | 6 | 0 |
30 Sep 16 | 2 | -15 | 5 | 0 |
30 Jun 16 | 1 | -12 | 4 | 0 |
31 Mar 16 | 1 | -10 | 4 | 0 |
31 Dec 15 | 1 | -9 | 4 | 0 |
30 Sep 15 | 0 | -8 | 3 | 0 |
30 Jun 15 | 0 | -6 | 3 | 0 |
31 Mar 15 | 0 | -4 | 2 | 0 |
31 Dec 14 | 0 | -3 | 1 | 0 |
30 Sep 14 | 0 | -2 | 1 | 0 |
30 Jun 14 | 0 | -1 | 1 | 0 |
31 Mar 14 | 0 | -1 | 0 | 0 |
Quality Earnings: CRBP is currently unprofitable.
Growing Profit Margin: CRBP is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CRBP is unprofitable, but has reduced losses over the past 5 years at a rate of 12.8% per year.
Accelerating Growth: Unable to compare CRBP's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CRBP is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-14%).
Return on Equity
High ROE: CRBP's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.